poisar

Stocks · News reference

BioLife Solutions To Be Acquired By Repligen For $31 Per Share In Cash And RGEN Stock At EV Of ~$1.5B

Benzinga Newsdesk

BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, which equates to a total value of $31.00 per share. This represents an implied premium of 24% to 90-day

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BLFSRGEN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  4. Halper Sadeh Llc

    Halper Sadeh LLC is Investigating Whether UTZ, BLFS, NRIM are Obtaining Fair Deals for their Shareholders

    Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties. Utz Brands is being acquired by Intersnack Group for $14.25 per share, BioLife Solutions is being sold to Repligen Corporation for $11.25 per share plus stock consideration, and Northrim BanCorp is merging with PBCO Financial Corporation. The firm is concerned that insiders may receive substantial benefits unavailable to ordinary shareholders and that transaction terms may limit competing offers.

    UTZBLFSNRIM
  5. Zacks.Com

    Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies

    Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.

    NVSRGENANIK